Affluent Medical : Coverage initiation by Kepler Cheuvreux.
Message d'erreur
- Notice : Undefined property: stdClass::$ds_changed dans eval() (ligne 16 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice : Undefined property: stdClass::$ss_search_api_url dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice : Undefined property: stdClass::$tm_title dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
Affluent Medical : Coverage initiation by Kepler Cheuvreux.
Affluent Medical Affluent Medical : Coverage initiation by Kepler Cheuvreux. Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. PRESS RELEASE Aix-en-Provence, 14 April 2022 - 17:45
Coverage initiation by Kepler Cheuvreux
Affluent Medical (ISIN code: FR0013333077 - Ticker: AFME), a French medtech specialising in the international development and industrialisation of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and mitral valve pathology, announces today that Kepler Cheuvreux has initiated coverage of the stock.
Affluent Medical now benefits from Kepler Cheuvreux' coverage with the publication of a financial note entitled "Kill three birds with one stone". This new note completes the coverage of the stock and enriches the consensus of analysts alongside Swisslife and Invest Securities. The financial analysis is available on the website: https://www.keplercheuvreux.com/, under "Research Public Access".
About Affluent Medical Affluent Medical is a French player in MedTech, founded by Truffle Capital, with the aim of becoming a global leader in the treatment of heart and vascular diseases, which are the leading cause of death worldwide, and of urinary incontinence, which today affects one in four adults. Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas. The four major technologies developed by the Company are currently in the pre-clinical and clinical study phase. Kalios is set to be the first medical device to be marketed in Europe. For more information, please visit: www.affluentmedical.com
Contacts:
Regulatory filing PDF file File: Affluent Medical - Kepler Cheuvreux EN |
|
|
Language: | English |
Company: | Affluent Medical |
320 avenue Archimède, Les pléiades III Bâtiment B | |
13100 Aix en Provence France | |
France | |
Phone: | +33 4 42 95 12 20 |
E-mail: | [email protected] |
Internet: | https://www.affluentmedical.com/ |
ISIN: | FR0013333077 |
Euronext Ticker: | AFME |
AMF Category: | Inside information / Other releases |
EQS News ID: | 1328901 |
End of Announcement | EQS News Service |
|
1328901 14-Apr-2022 CET/CEST